Learning Objectives:

• Enhance understanding of eye toxicity related to emerging anticancer drugs with a focus on ADCs—acute, delayed, and anticipatory types—along with their pathophysiology and variability in patient experiences
• Emphasize the importance of proactive management and monitoring
• Promote collaboration within multidisciplinary teams (MDTs) and discuss when and why to drive the patient to the ophthalmologist
• Gain valuable insights into patients’ experiences to better understand the impact of eye toxicity

Agenda:

• Introduction – Prof. Florian Scotté (Chair)
• Emerging Drugs, Emerging Toxicities and Eyes: Why and How Can We Anticipate During Drug Development? – Prof. Mario Mandalà
• The Impact of Eye Toxicity in the Oncological Practice, Are There Guidelines? – Dr. Iphigénie Korakis
• From Basic to Specialized Management: The Ophthalmologist Perspective – Dr. Grégoire Chevreau
• The Patient Perspective: Impact and Outcomes in the Short and Long Term - Amy Russell-Parliman (Patient Advocate)
• Q & A

This webinar was made possible by an unrestricted grant from Daiichi Sankyo Europe/Astra Zeneca.